Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.34 |
| ▸ | CETP | P11597 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15348386 | 0.94 | GPR119 (0.37) | ABCB1GPR119STSKDM4EPKM | |
| SCHEMBL15348384 | 0.94 | GPR119 (0.37) | ABCB1GPR119STSKDM4EPKM | |
| SCHEMBL13759689 | 0.87 | ABCB1 (0.40) | ABCB1GPR119STSKDM4EPKM | |
| SCHEMBL29007758 | 0.87 | ABCB1 (0.38) | ABCB1GPR119STSKDM4EPKM | |
| SCHEMBL1769258 | 0.87 | ABCB1 (0.38) | ABCB1GPR119STSKDM4EPKM | |
| SCHEMBL17948125 | 0.87 | ABCB1 (0.38) | ABCB1GPR119STSKDM4EPKM | |
| SCHEMBL31224155 | 0.87 | ABCB1 (0.40) | ABCB1GPR119STSKDM4EPKM | |
| SCHEMBL31224004 | 0.86 | ABCB1 (0.37) | ABCB1GPR119STSKDM4EPKM | |
| SCHEMBL29282039 | 0.85 | ABCB1 (0.38) | ABCB1GPR119STSKDM4EPKM | |
| SCHEMBL13759697 | 0.83 | ABCB1 (0.35) | ABCB1GPR119STSKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513085-B1 | BICYCLIC COMPOUNDS AS ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2016-09-28 | — | — | EP | disclosed |
| EP-2519514-B1 | ALPHA4BETA2 NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2015-08-26 | — | — | EP | disclosed |
| US-8735423-B2 | Bicyclic compounds as α4β2 nicotinic acetylcholine receptor ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-05-27 | — | — | US | disclosed |
| US-8653071-B2 | α4β2 neuronal nicotinic acetylcholine receptor ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-02-18 | — | — | US | disclosed |
| US-20130072518-A1 | BICYCLIC COMPOUNDS AS alpha4 beta2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Suven Life Science Limited (IN) | 2013-03-21 | — | — | US | disclosed |
| US-20120322808-A1 | Alpha 4 Beta 2 NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2012-12-20 | — | — | US | disclosed |
| EP-2519514-A2 | ALPHA4BETA2 NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Suven Life Sciences Limited (IN) | 2012-11-07 | — | — | EP | disclosed |
| EP-2513085-A1 | BICYCLIC COMPOUNDS AS alpha4beta2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Suven Life Sciences Limited (IN) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011080751-A2 | α4β2 NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011061751-A1 | BICYCLIC COMPOUNDS AS α4β2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072518-A1 | BICYCLIC COMPOUNDS AS alpha4 beta2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA4, CHRNB4, CHRNA2 | ABCB1 819/4885GPR119 239/4885STS 3837/4885 |
| US-20120322808-A1 | Alpha 4 Beta 2 NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNB2, CHRNB4, CHRNA4 | ABCB1 2033/4885GPR119 112/4885STS 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.